Special Issue

Novel Therapeutic Targets of Prostate Cancer

Message from the Guest Editor

The management of advanced prostate cancer has largely evolved during the last decade. Several new drugs have been demonstrated to be life-prolonging, even in the setting of metastatic castration-resistant prostate cancer. Future research focuses on different molecular pathways, such as PTEN loss or DNA repair defects, and has potential for near-future applications. New horizons have also opened in the era of immunotherapy and PARP inhibitors. Several trials are ongoing to assess the oncologic efficacy and safety of new molecules, alone or in combination. Radioligand therapy also emerged as a promising therapeutic option, following the impressive progress of new generation imaging modalities. All these treatments are changing the paradigms in advanced prostate cancer treatment. This Special Issue will publish up-to-date data on novel therapeutic targets in prostate cancer management.

Guest Editor

Dr. Guillaume Ploussard

Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France

Deadline for manuscript submissions

closed (15 December 2021)



Journal of Clinical <u>Medici</u>ne

an Open Access Journal by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/70478

Journal of Clinical Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).